Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/O/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:10:31 (17)	[redacted]20[redacted]:15:40 (2)/ 2	臨床検査/ 血中クレアチニン増加/ CREATININE INCREASED#	RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (2)/ [redacted]20[redacted]:09:41 (2)	[redacted]20[redacted]:13:30 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (10)/ [redacted]20[redacted]:10:19 (11)	[redacted]20[redacted]:13:35 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (16)/ [redacted]20[redacted]:22:24 (16)	[redacted]20[redacted]:15:40 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/W/F)	/ [redacted]20[redacted]:13:23 (2)	[redacted]20[redacted]:11:00	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]20[redacted]:14:18 (16)	[redacted]20[redacted]:10:55	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]20[redacted] (29)	[redacted]20[redacted]:13:25	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/F)	/ [redacted]20[redacted]:15:55 (8)	[redacted]20[redacted]:11:40	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/F)	/ [redacted]20[redacted]:14:37 (16)	[redacted]20[redacted]:10:55	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]20[redacted]:14:30 (34)	[redacted]20[redacted]:11:20	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/W/M)	[redacted]20[redacted] (6)/ [redacted]20[redacted]:21:00 (6)	[redacted]20[redacted]:11:10 (6)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (16)/ [redacted]20[redacted]:14:00 (16)	[redacted]20[redacted]:10:15 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/W/M)	[redacted]20[redacted] (36)/ [redacted]20[redacted] (37)	[redacted]20[redacted]:11:11 (1)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME (CRS)#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (8[redacted]/M/W/S)	[redacted]20[redacted] (20)/ [redacted]20[redacted]:11:49 (22)	[redacted]20[redacted]:10:22 (6)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME (CRS)#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (27)/ [redacted]20[redacted]:10:51 (29)	[redacted]20[redacted]:10:22 (13)/ 3	呼吸器、胸郭および縦隔障害/ 呼吸困難/ WORSENING OF DYSPNEA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (55)/ [redacted]20[redacted]:21:50 (56)	[redacted]20[redacted]:11:02 (6)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (8[redacted]/M/W/S)	[redacted] 20[redacted] (58)/ [redacted] 20[redacted]:14:59 (58)	[redacted] 20[redacted]:11:02 (9)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted] 20[redacted] (101)/ [redacted] 20[redacted]:19:27 (107)	[redacted] 20[redacted]:10:40 (2)/ 7	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted] 20[redacted] (148)/ [redacted] 20[redacted]:14:58 (203)	[redacted] 20[redacted]:11:14 (7)/ 56	感染症および寄生虫症/ ＣＯＶＩＤ－１９/ COVID－19	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (8[redacted]/M/W/S)	[redacted] 20[redacted] (54)/ [redacted] 20[redacted] (64)	[redacted] 20[redacted]:12:00 (9)/ 11	感染症および寄生虫症/ 限局性感染/ INFECTION LEFT ARM#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (8[redacted]/M/W/S)	[redacted]20[redacted] (5)/ [redacted]20[redacted]:09:28 (7)	[redacted]20[redacted]:10:45 (5)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (15)/ [redacted]20[redacted]:08:00 (16)	[redacted]20[redacted]:11:25 (1)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (48)	[redacted]20[redacted]:12:00 (3)	一般・全身障害および投与部位の状態/ 末梢性浮腫/ DISTAL EDEMA#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (47)/ [redacted]20[redacted]:14:40 (48)	[redacted]20[redacted]:12:00 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (8[redacted]/M/W/S)	[redacted]20[redacted] (64)	[redacted]20[redacted]:12:00 (19)	一般・全身障害および投与部位の状態/ 倦怠感/ MALAISE#	RELATED/ SAE [H]/ N	Grade 3 (2)/ DOSE DELAYED	N/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (54)/ [redacted]20[redacted] (54)	[redacted]20[redacted]:12:00 (9)/ 1	傷害、中毒および処置合併症/ 転倒/ FALL#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (77)/ [redacted]20[redacted] (78)	[redacted]20[redacted]:12:00 (32)/ 2	感染症および寄生虫症/ 壊死性筋膜炎/ NECROTIZING FASCIITIS	NOT RELATED/ SAE [F, L, H]/ N	Grade 5 (4)/ NOT APPLICABLE	Y/ FATAL
[redacted] (8[redacted]/F/W/D)	[redacted]20[redacted] (7)/ [redacted]20[redacted]:08:03 (7)	[redacted]20[redacted]:11:16 (7)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (8[redacted]/M/W/F)	/ [redacted]20[redacted]:22:43 (2)	[redacted]20[redacted]:10:30	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]20[redacted]:01:00 (17)	[redacted]20[redacted]:16:20	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]20[redacted]:13:10 (22)	[redacted]20[redacted]:16:20	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (99)/ [redacted]20[redacted] (118)	[redacted]20[redacted]:10:35 (15)/ 20	感染症および寄生虫症/ 感染性胸水/ PLEURA EMPYEM	RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/W/F)	[redacted]20[redacted] (9)/ [redacted]20[redacted] (10)	[redacted]20[redacted]:10:30 (2)/ 2	神経系障害/ 浮動性めまい/ DIZZINESS#	RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (15)/ [redacted]20[redacted]:22:05 (16)	[redacted]20[redacted]:10:15 (1)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]20[redacted]:13:12 (19)	[redacted]20[redacted]:10:15	臨床検査/ Ｃ－反応性蛋白増加/ INCREASING CRP#	RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/W/F)	[redacted]20[redacted] (154)/ [redacted]20[redacted] (154)	[redacted]20[redacted]:14:15 (56)/ 1	感染症および寄生虫症/ 敗血症/ SEPSIS$	NOT RELATED/ SAE [F, H]/ N	Grade 5 (3)/ NOT APPLICABLE	N/ FATAL

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/W/F)	[redacted]20[redacted] (133)	[redacted]20[redacted]:14:15 (35)	感染症および寄生虫症/ 敗血症性ショック/ SEPTIC SHOCK (PROBABLY ABDOMINAL ORIGIN)$	NOT RELATED/ SAE [L, H]/ N	Grade 4/ NOT APPLICABLE	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (133)	[redacted]20[redacted]:14:15 (35)	腎および尿路障害/ 急性腎障害/ RENAL ACUTE FAILURE$	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (4[redacted]/M/W/F)	[redacted]20[redacted] (22)/ [redacted]20[redacted] (25)	[redacted]20[redacted]:14:05 (8)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (94)/ [redacted]20[redacted] (112)	[redacted]20[redacted]:15:46 (11)/ 19	感染症および寄生虫症/ニューモシスチス・イロベチイ肺炎/ INTERSTITIAL PNEUMONIA DUE TO PNEUMOCYSTIS JIROVECII	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/M/W/F)	[redacted]20[redacted] (2)/ [redacted]20[redacted] (3)	[redacted]20[redacted]:15:59 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (15)/ [redacted]20[redacted] (18)	[redacted]20[redacted]:14:05 (1)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 3 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (4[redacted]/F/W/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (21)	[redacted]20[redacted]:14:15 (2)/ 6	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (22)/ [redacted]20[redacted] (23)	[redacted]20[redacted]:14:36 (8)/ 2	一般・全身障害および投与部位の状態/ 発熱/ FEVER OF UNKNOWN ORIGIN#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/F)	[redacted] (99)	[redacted] :14:41 (22)	胃腸障害/ 小腸炎/ ILEITIS	RELATED/ SAE [H]/ N	Grade 3 (2)/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted] (114)	[redacted] :16:22 (24)	感染症および寄生虫症/ 敗血症性ショック/ SEPTIC SHOCK	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted] (16)/ [redacted] (18)	[redacted] :14:36 (2)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (4[redacted]/F/W/F)	/ [redacted] (72)	[redacted] :09:15	腎および尿路障害/ 尿閉/ URINARY RETENTION	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/W/F)	[redacted]20[redacted] (308)/ [redacted]20[redacted] (312)	[redacted]20[redacted]:13:25 (20)/ 5	感染症および寄生虫症/ ＣＯＶＩＤ－１９/ COVID INFECTION	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/S)	[redacted]20[redacted] (38)/ [redacted]20[redacted] (70)	[redacted]20[redacted]:11:25 (7)/ 33	感染症および寄生虫症/ サイトメガロウイルス感染再燃/ CYTOMEGALOVIRUS INFECTION REACTIVATION#	RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (16)/ [redacted]20[redacted]:09:45 [redacted]20[redacted]:12:00 (2)/ 1		免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/W/M)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (17)	[redacted]20[redacted]:10:40 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CRS#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (8)/ [redacted]20[redacted] (9)	[redacted]20[redacted]:18:09 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (122)/ [redacted]20[redacted] (138)	[redacted]20[redacted]:11:00 (11)/ 17	血液およびリンパ系障害/ 発熱性好中球減少症/ FEBRILE NEUTROPHENIA	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (122)/ [redacted]20[redacted] (138)	[redacted]20[redacted]:11:00 (11)/ 17	感染症および寄生虫症/ ブドウ球菌性菌血症/ BACTEREMIA (STAPHYLOCOCCUS EPIDERMIS)	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (144)/ [redacted]20[redacted] (144)	[redacted]20[redacted]:11:00 (33)/ 1	感染症および寄生虫症/ 敗血症性ショック/ SEPTIC SHOCK	NOT RELATED/ SAE [F, L]/ N	Grade 5/ DRUG WITHDRAWN	Y/ FATAL

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (3)/ [redacted]20[redacted] (4)	[redacted]20[redacted]:12:47 (3)/ 2	感染症および寄生虫症/ 細菌性上気道感染/ UPPER RESPIRATORY INFECTION BY PNEUMOCOCCUS#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/N/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:13:20 (16)	[redacted]20[redacted]:13:26 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (17)/ [redacted]20[redacted] (18)	[redacted]20[redacted]:13:26 (3)/ 2	代謝および栄養障害/ 高血糖/ HYPERGLYCEMIA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/N/F)	[redacted]20[redacted] (6)/ [redacted]20[redacted] (11)	[redacted]20[redacted]:14:14 (6)/ 6	胃腸障害/ 腹痛/ ABDOMINAL PAIN#	RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/N/F)	[redacted]20[redacted] (15)	[redacted]20[redacted]:18:20 (1)	一般・全身障害および投与部位の状態/ 疲労/ FATIGUE#	NOT RELATED/ SAE [H, D]/ N	Grade 3/ DOSE NOT CHANGED	N/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (17)/ [redacted]20[redacted]:16:00 (18)	[redacted]20[redacted]:18:20 (3)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/N/F)	[redacted]20[redacted] (20)/ [redacted]20[redacted] (24)	[redacted]20[redacted]:15:35 (6)/ 5	感染症および寄生虫症/ 髄膜炎/ MENINGITIS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/N/F)	[redacted]20[redacted] (21)/ [redacted]20[redacted] (24)	[redacted]20[redacted]:15:55 (7)/ 4	感染症および寄生虫症/ 尿路感染/ URINARY TRACT INFECTION#	NOT RELATED/ SAE [H]/ N	Grade 3 (2)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/M/N/F)	[redacted]20[redacted] (21)/ [redacted]20[redacted] (23)	[redacted]20[redacted]:14:25 (7)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/N/F)	[redacted]20[redacted] (18)/ [redacted]20[redacted] (19)	[redacted]20[redacted]:13:30 (4)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H, O]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/N/F)	[redacted]20[redacted] (284)/ [redacted]20[redacted] (289)	[redacted]20[redacted]:13:40 (10)/ 6	呼吸器、胸郭および縦隔障害/ 肺陰影/ DIFFUSE PNEUMOPATHY	NOT RELATED/ SAE [F, L, H]/ N	Grade 5 (4)/ NOT APPLICABLE	Y/ FATAL
[redacted] (6[redacted]/F/N/F)	[redacted]20[redacted] (342)	[redacted]20[redacted]:14:23 (48)	感染症および寄生虫症/ ＣＯＶＩＤ－１９肺炎/ ＣＯＶＩＤ－１９ PNEUMONIA	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	Y/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/N/F)	[redacted]20[redacted] (18)/ [redacted]20[redacted] (23)	[redacted]20[redacted]:16:07 (4)/ 6	感染症および寄生虫症/ 腎盂腎炎/ PYELONEPHRITIS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/N/F)	[redacted]20[redacted] (24)/ [redacted]20[redacted]:06:30 (29)	[redacted]20[redacted]:11:50 (16)/ 6	代謝および栄養障害/ ２型糖尿病/ WORSENING OF TYPE 2 DIABETES MELLITUS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (17)/ [redacted]20[redacted]:09:00 (18)	[redacted]20[redacted]:12:10 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/N/F)	[redacted]20[redacted] (8)/ [redacted]20[redacted] (14)	[redacted]20[redacted]:11:42 (8)/ 7	代謝および栄養障害/ ２型糖尿病/ WORSENING TYPE 2 DIABETES MELLITUS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/N/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:12:00 (16)	[redacted]20[redacted]:12:40 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (16)/ [redacted]20[redacted]:15:00 (16)	[redacted]20[redacted]:12:40 (2)/ 1	神経系障害/ 免疫エフェクター細胞関連神経毒性症候群/ IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/N/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:22:00 (19)	[redacted]20[redacted]:14:39 (2)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/N/F)	[redacted]20[redacted] (23)/ [redacted]20[redacted] (29)	[redacted]20[redacted]:12:00 (8)/ 7	代謝および栄養障害/ ２型糖尿病/ WORSENING DIABETES MELLITUS TYPE 2#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/N/F)	[redacted]20[redacted] (17)/ [redacted]20[redacted]:13:30 (18)	[redacted]20[redacted]:12:00 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/W/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (33)	[redacted]20[redacted]:11:00 (2)/ 18	感染症および寄生虫症/ ブドウ球菌感染/ STAPHYLOCOCCUS EPIDERMIDIS INFECTION#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/W/F)	[redacted]20[redacted] (20)/ [redacted]20[redacted]:18:00 (20)	[redacted]20[redacted]:15:02 (6)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/W/F)	[redacted]20[redacted] (2)/ [redacted]20[redacted]:16:19 (3)	[redacted]20[redacted]:13:28 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/A/M)	[redacted] 20[redacted] (17)/ [redacted] 20[redacted] (19)	[redacted] 20[redacted]:14:47 (10)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME.#	RELATED/ SAE [H]/ Y	Grade 3 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/A/F)	[redacted] 20[redacted] (29)/ [redacted] 20[redacted] (37)	[redacted] 20[redacted]:11:55 (8)/ 9	代謝および栄養障害/ 高血糖/ HYPERGLYCEMIA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] 20[redacted] (23)/ [redacted] 20[redacted] (46)	[redacted] 20[redacted]:11:55 (2)/ 24	代謝および栄養障害/ 食欲減退/ ANOREXIA#	RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] 20[redacted] (29)/ [redacted] 20[redacted] (37)	[redacted] 20[redacted]:11:55 (8)/ 9	腎および尿路障害/ 急性腎障害/ ACUTE KIDNEY INJURY#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/A/F)	[redacted] (68)/ [redacted] :08:30 (74)	[redacted] :15:49 (12)/ 7	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME	RELATED/ SAE [H]/ Y	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/A/F)	[redacted] (99)/ [redacted] :08:59 (119)	[redacted] :12:00 (36)/ 21	神経系障害/ ベル麻痺/ BELL'S PALSY	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted] (16)/ [redacted] :10:00 (16)	[redacted] :11:20 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (71)/ [redacted] :10:00 (80)	[redacted] :12:00 (8)/ 10	感染症および寄生虫症/ 肺炎/ PNEUMONIA	RELATED/ SAE [H]/ N	Grade 3 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/N/F)	[redacted] 20[redacted] (17)/ [redacted] 20[redacted]:06:27 (21)	[redacted] 20[redacted]:14:42 (2)/ 5	免疫系障害/ サイトカイン放出症候群/ CYTOKYNE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/W/F)	[redacted] 20[redacted] (5)/ [redacted] 20[redacted] (6)	[redacted] 20[redacted]:14:45 (5)/ 2	皮膚および皮下組織障害/ 発疹/ EXANTHEMA (FACE)#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] 20[redacted] (16)/ [redacted] 20[redacted] (19)	[redacted] 20[redacted]:15:57 (8)/ 4	感染症および寄生虫症/ 肺炎/ PULMONARY INFECTION#	RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted] 20[redacted] (23)/ [redacted] 20[redacted] (26)	[redacted] 20[redacted]:12:00 (6)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/W/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (20)	[redacted]20[redacted]:13:16 (2)/ 5	呼吸器、胸郭および縦隔障害/ 胸水/ WORSENING OF PLEURAL EFFUSION LEFT LUNG#	RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (2)/ [redacted]20[redacted] (2)	[redacted]20[redacted]:13:46 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (16)/ [redacted]20[redacted] (17)	[redacted]20[redacted]:13:16 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (8[redacted]/F/W/F)	[redacted]20[redacted] (22)/ [redacted]20[redacted] (22)	[redacted]20[redacted]:14:19 (8)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/W/F)	[redacted]20[redacted] (20)/ [redacted]20[redacted] (22)	[redacted]20[redacted]:10:37 (6)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (15)/ [redacted]20[redacted]:11:54 (16)	[redacted]20[redacted]:10:37 (1)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (4[redacted]/M/A/F)	[redacted]20[redacted] (15)/ [redacted]20[redacted]:12:00 (16)	[redacted]20[redacted]:10:14 (1)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/W/M)	[redacted]20[redacted] (59)/ [redacted]20[redacted] (60)	[redacted]20[redacted]:11:30 (3)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/W/M)	[redacted]20[redacted] (84)/ [redacted]20[redacted] (127)	[redacted]20[redacted]:12:20 (7)/ 44	感染症および寄生虫症/ 咽頭炎/ PHARYNGITIS	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (145)	[redacted]20[redacted]:12:20 (68)	感染症および寄生虫症/ 気管支肺アスペルギルス症/ PULMONARY ASPERGILLOSIS INFECTION LYMPHOMA LOCALIZATION/ ABNORMALITIES PERSISTENT PULMONARY LESIONS$	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (28)/ [redacted]20[redacted] (29)	[redacted]20[redacted]:11:00 (6)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (4[redacted]/F/W/F)		[redacted]20[redacted]:12:35	感染症および寄生虫症/ ＣＯＶＩＤ－１９/ COVID 19 INFECTION	RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	Y/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/M/W/F)	/ [redacted]20[redacted] (13)	[redacted]20[redacted]:13:15	神経系障害/ 頭痛/ HEADACHE#	RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]20[redacted] (22)	[redacted]20[redacted]:13:25	血液およびリンパ系障害/ リンパ節痛/ WORSENING LYMPH NODE PAIN#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/F/W/F)	[redacted]20[redacted] (113)/ [redacted]20[redacted] (163) (29)/ 51	[redacted]20[redacted]:12:14	呼吸器、胸郭および縦隔障害/ 呼吸困難/ WORSENING DYSPONOEA	NOT RELATED/ SAE [H]/ N	/ NOT APPLICABLE	N/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/W/F)	[redacted]20[redacted] (13)/ [redacted]20[redacted]:08:10 (15)	[redacted]20[redacted]:15:09 (6)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/W/F)	[redacted]20[redacted] (23)/ [redacted]20[redacted] (24)	[redacted]20[redacted]:16:11 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:14:15 (17)	[redacted]20[redacted]:16:08 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME (CRS)#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (31)/ [redacted]20[redacted]:12:09 (41)	[redacted]20[redacted]:16:08 (17)/ 11	感染症および寄生虫症/ 感染による気管支拡張症の増悪/ INFECTIVE EXACERBATION OF BRONCHIECTASIS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (83)/ [redacted]20[redacted] (89)	[redacted]20[redacted]:15:36 (20)/ 7	皮膚および皮下組織障害/ 発疹/ RASH RIGHT SHIN	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	N/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/W/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (18)	[redacted]20[redacted]:14:00 (2)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (20)/ [redacted]20[redacted] (24)	[redacted]20[redacted]:13:30 (6)/ 5	一般・全身障害および投与部位の状態/ 発熱/ FEVER#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (28)/ [redacted]20[redacted] (34)	[redacted]20[redacted]:16:30 (6)/ 7	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (56)/ [redacted]20[redacted] (60)	[redacted]20[redacted]:14:10 (11)/ 5	感染症および寄生虫症/ 水痘帯状疱疹ウイルス感染/ VARICELLA ZOSTER VIRUS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (95)/ [redacted]20[redacted] (100)	[redacted]20[redacted]:12:00 (1)/ 6	感染症および寄生虫症/ 肺炎/ COMMUNITY ACQUIRED PNEUMONIA	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (12)/ [redacted]20[redacted] (17)	[redacted]20[redacted]:14:33 (5)/ 6	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted]	[redacted]20[redacted] (20)/ [redacted]20[redacted] (32)	[redacted]20[redacted]:13:40 (6)/ 13	一般・全身障害および投与部位の状態/ 発熱/ FEVER OF UNKNOWN ORIGIN#	RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/F/W/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (17)	[redacted]20[redacted]:14:15 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/F/W/F)	[redacted]20[redacted] (36)/ [redacted]20[redacted] (42)	[redacted]20[redacted]:15:03 (8)/ 7	感染症および寄生虫症/ 帯状疱疹/ SHINGLES#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (8[redacted]/M/W/F)	[redacted]20[redacted] (19)/ [redacted]20[redacted]:08:29 (20)	[redacted]20[redacted]:12:52 (5)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/W/F)	[redacted]20[redacted] (357)	[redacted]20[redacted]:14:26 (40)	感染症および寄生虫症/ ＣＯＶＩＤ－１９肺炎/ COVID PNEUMONIA	NOT RELATED/ SAE [H]/ N	Grade 3 (2)/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:05:34 (17)	[redacted]20[redacted]:13:49 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (8[redacted]/M/W/F)	[redacted]20[redacted] (47)/ [redacted]20[redacted]:05:24 (54)	[redacted]20[redacted]:12:20 (12)/ 8	感染症および寄生虫症/ ＣＯＶＩＤ－１９肺炎/ ＣＯＶＩＤ－１９ PNEUMONIA#	NOT RELATED/ SAE [F, L, H, D]/ N	Grade 5 (2)/ NOT APPLICABLE	Y/ FATAL
[redacted] (6[redacted]/M/W/F)	[redacted]20[redacted] (57)/ [redacted]20[redacted]:02:00 (57)	[redacted]20[redacted]:10:52 (8)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/W/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:08:00 (17)	[redacted]20[redacted]:12:46 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/A/M)	[redacted]20[redacted] (21)	[redacted]20[redacted]:11:42 (3)	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (8[redacted]/F/W/M)	[redacted]20[redacted] (6)/ [redacted]20[redacted] (126)	[redacted]20[redacted]:14:50 (6)/ 121	一般・全身障害および投与部位の状態/ 顔面痛/ WORSENING FACIAL PAIN#	NOT RELATED/ SAE [H]/ N	Grade 3 (2)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/M)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:08:00 (17)	[redacted]20[redacted]:15:43 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H, O]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (75)	[redacted]20[redacted]:10:38 (5)	感染症および寄生虫症/ ＣＯＶＩＤ－１９肺炎/ COVID 19 LUNG INFECTION	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/M)	[redacted]20[redacted] (8)/ [redacted]20[redacted] (34)	[redacted]20[redacted]:11:52 (1)/ 27	代謝および栄養障害/ 食欲減退/ ANOREXIA#	NOT RELATED/ SAE [H]/ N	Grade 3 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (12)/ [redacted]20[redacted] (15)	[redacted]20[redacted]:11:52 (5)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [L, H]/ Y	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (8)/ [redacted]20[redacted] (45)	[redacted]20[redacted]:11:52 (1)/ 38	心臓障害/ 洞結節機能不全/ TACHYBRADY SYNDROME WITH MANAGEMENT OF SEMI-PERMANENT PACEMAKER.#	NOT RELATED/ SAE [H]/ N	Grade 4 (3)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/M)	[redacted]20[redacted] (30)/ [redacted]20[redacted] (31)	[redacted]20[redacted]:11:44 (9)/ 2	傷害、中毒および処置合併症/ 頭部損傷/ HEADWOUND#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/M)	[redacted]20[redacted] (23)/ [redacted]20[redacted] (37)	[redacted]20[redacted]:11:10 (16)/ 15	呼吸器、胸郭および縦隔障害/ 胸水/ WORSENING OF PLEURAL EFFUSION#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted]20[redacted] (21)/ [redacted]20[redacted] (137)	[redacted]20[redacted]:12:15 (7)/ 117	血管障害/ 血栓症/ THROMBOSIS RIGHT ARM#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted]20[redacted] (58)/ [redacted]20[redacted] (63)	[redacted]20[redacted]:14:30 (7)/ 6	呼吸器、胸郭および縦隔障害/ 胸水/ WORSENING OF PLEURAL EFFUSION	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted]20[redacted] (67)/ [redacted]20[redacted] (75)	[redacted]20[redacted]:13:12 (8)/ 9	呼吸器、胸郭および縦隔障害/ 胸水/ WORSENING OF PLEURA EFFUSION	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/M)	[redacted]20[redacted] (67)/ [redacted]20[redacted]:13:00 (75)	[redacted]20[redacted]:13:12 (8)/ 9	感染症および寄生虫症/ 帯状疱疹/ SHINGLES	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
		[redacted]20[redacted]:11:25	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/基底細胞癌/BASAL CELL CARCINOMA ON NASAL TIP	NOT RELATED/ SAE [H, O]/ N	Grade 2/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (5[redacted]/M/O/M)	[redacted]20[redacted] (9)/ [redacted]20[redacted]:18:42 (9)	[redacted]20[redacted]:16:40 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (15)/ [redacted]20[redacted]:11:25 (19)	[redacted]20[redacted]:17:30 (2)/ 5	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROM#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/O/M)	[redacted] (19)/ [redacted] :08:40 (47)	[redacted] :17:30 (6)/ 29	腎および尿路障害/ 急性腎障害/ ACUTE KIDNEY INJURY#	RELATED/ SAE [L, H]/ N	Grade 4 (2)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/M)	[redacted] (19)/ [redacted] (23)	[redacted] :10:39 (5)/ 5	一般・全身障害および投与部位の状態/ 発熱/ FEVER OF POSSIBLE RESPIRATORY ORIGIN#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (31)	[redacted] :15:35 (3)	感染症および寄生虫症/ 皮膚感染/ RIGHT ARM CUTANEOUS INFECTION#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (4[redacted]/M/W/M)	[redacted] (12)/ [redacted] (16)	[redacted] :18:04 (5)/ 5	感染症および寄生虫症/ 気管支炎/ BRONCHITIS (PREVIOUSLY REPORTED AS RIGHT BASAL PNEUMONIA)#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/M/W/M)	[redacted]20[redacted] (27)/ [redacted]20[redacted] (32)	[redacted]20[redacted]:19:30 (6)/ 6	呼吸器、胸郭および縦隔障害/ 胸水/ PLEURAL EFFUSION#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (37)/ [redacted]20[redacted] (87)	[redacted]20[redacted]:16:07 (2)/ 51	呼吸器、胸郭および縦隔障害/ 胸水/ RECURRENT PLEURAL EFFUSION#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (73)/ [redacted]20[redacted] (102)	[redacted]20[redacted]:14:27 (8)/ 30	感染症および寄生虫症/ 蓄膿/ EMPYEMA LOCULATED BY E.COLI MULTIS	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (17)/ [redacted]20[redacted] (22)	[redacted]20[redacted]:16:17 (2)/ 6	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/W/M)	[redacted] (9)/ [redacted] (10)	[redacted] :13:35 (2)/ 2	神経系障害/ 免疫エフェクター細胞関連神経毒性症候群/ ICANS#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (9)/ [redacted] (11)	[redacted] :13:35 (2)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (20)/ [redacted] (21)	[redacted] :14:46 (4)/ 2	血液およびリンパ系障害/ 好中球減少症/ NEUTROPENIA WORSENING#	NOT RELATED/ SAE [O]/ N	Grade 4/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (18)/ [redacted] :16:05 (20)	[redacted] :14:46 (2)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [L, H]/ Y	Grade 3 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/W/M)	[redacted]20[redacted] (19)/ [redacted]20[redacted]:08:19 (31)	[redacted]20[redacted]:14:46 (3)/ 13	血液およびリンパ系障害/ 血小板減少症/ THROMBOCYTOPENIA WORSENING#	NOT RELATED/ SAE [O]/ N	Grade 4/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (33)/ [redacted]20[redacted]:08:33 (38)	[redacted]20[redacted]:18:15 (3)/ 6	血液およびリンパ系障害/ 血小板減少症/ THROMBOCYTOPENIA WORSENING#	NOT RELATED/ SAE [O]/ N	Grade 4/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (45)	[redacted]20[redacted]:18:15 (8)	血液およびリンパ系障害/ 好中球減少症/ NEUTROPENIA WORSENING#	NOT RELATED/ SAE [O]/ N	Grade 4/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (45)	[redacted]20[redacted]:18:15 (8)	血液およびリンパ系障害/ 血小板減少症/ THROMBOCYTOPENIA WORSENING#	NOT RELATED/ SAE [O]/ N	Grade 4/ DOSE DELAYED	N/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/W/M)	[redacted] (10)/ [redacted] (27)	[redacted] :13:31 (3)	胃腸障害/ 腹部腫瘤/ WORSENING OF ABDOMINAL PAIN DUE TO ABDOMINAL MASS#	NOT RELATED/ SAE [H, D]/ N	Grade 3/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (8[redacted]/M/A/M)	[redacted] (57)/ [redacted] (57)	[redacted] :12:13 (29)/ 1	傷害、中毒および処置合併症/ 脊椎圧迫骨折/ T12 COMPRESSION FRACTURE#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	N/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/A/M)	[redacted] (16)/ [redacted] :07:00 (19)	[redacted] :10:00 (2)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/A/M)	[redacted] (23)/ [redacted] (25)	[redacted] :12:22 (2)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H, O]/ Y	Grade 3 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/M)	[redacted] (16)/ [redacted] :06:29 (22)	[redacted] :14:40 (2)/ 7	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/A/M)	[redacted] (6)/ [redacted] (8)	[redacted] :17:35 (6)/ 3	感染症および寄生虫症/ 誤嚥性肺炎/ ASPIRATION PNEUMONIA#	NOT RELATED/ SAE [F, L, H]/ N	Grade 5 (3)/ DOSE NOT CHANGED	Y/ FATAL
[redacted] (6[redacted]/M/W/M)	[redacted] (16)/ [redacted] :11:38 (23)	[redacted] :11:54 (2)/ 8	感染症および寄生虫症/ 敗血症/ SEPSIS#	RELATED/ SAE [L, H]/ N	Grade 4 (3)/ DRUG WITHDRAWN	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/W/M)	[redacted] (27)/ [redacted] (29)	[redacted] :13:26 (4)/ 3	心臓障害/ 心房細動/ ATRIAL FIBRILLATION#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/W/M)	[redacted] 20[redacted] (15)/ [redacted] 20[redacted] (18)	[redacted] 20[redacted]:10:18 (1)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/F/W/M)	[redacted] 20[redacted] (22)/ [redacted] 20[redacted] (22)	[redacted] 20[redacted]:12:33 (1)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (8[redacted]/M/W/M)	[redacted] 20[redacted] (2)/ [redacted] 20[redacted] (2)	[redacted] 20[redacted]:13:10 (2)/ 1	傷害、中毒および処置合併症/ 転倒/ FALL#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/M)	[redacted] 20[redacted] (6)/ [redacted] 20[redacted] (12)	[redacted] 20[redacted]:16:23 (6)/ 7	胃腸障害/ 上部消化管出血/ UPPER GASTROINTESTINAL BLEED#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/M)	[redacted]20[redacted] (7)/ [redacted]20[redacted] (12)	[redacted]20[redacted]:16:23 (7)/ 6	血管障害/ 血液量減少性ショック/ HYPOVOLEMIC SHOCK#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (21)/ [redacted]20[redacted] (26)	[redacted]20[redacted]:12:02 (2)/ 6	一般・全身障害および投与部位の状態/ 多臓器機能不全症候群/ MULTIORGAN FAILURE#	RELATED/ SAE [L, H]/ N	Grade 4/ DRUG WITHDRAWN	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (20)	[redacted]20[redacted]:12:02 (1)	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [L, H, O]/ Y	Grade 4/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (5[redacted]/M/W/M)	[redacted]20[redacted] (17)/ [redacted]20[redacted] (18)	[redacted]20[redacted]:22:38 (3)	神経系障害/ 頭痛/ HEADACHE (WORSENING)#	RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/M)	[redacted]20[redacted] (20)/ [redacted]20[redacted] (27)	[redacted]20[redacted]:01:00 (5)/ 8	感染症および寄生虫症/ ウイルス性上気道感染/ UPPER RESPIRATORY INFECTION- RHINOVIRUS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (21)/ [redacted]20[redacted] (52)	[redacted]20[redacted]:01:00 (6)/ 32	胃腸障害/ 腹痛/ ABDOMINAL PAIN#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (8[redacted]/M/W/M)		[redacted]20[redacted]:13:47	胃腸障害/ 下痢/ DIARRHEA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED
		[redacted]20[redacted]:13:47	呼吸器、胸郭および縦隔障害/ 呼吸困難/ DYSPNEA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[M]CL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Table 71

Serious Adverse Events - GCT3013-04 Escalation Part - Subjects in All Cohorts - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset D/T Resolution D/T (Study Day)	Most Recent Dose D/T (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/M/A(JAPANESE)/H)	[redacted]20[redacted] (-42) [redacted]20[redacted] (-42)	20[redacted] 1	神経系障害/ 傾眠/ SOMNOLENCE*	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (26)	[redacted]20[redacted]:12:31 (5)	神経系障害/ 意識レベルの低下/ DEPRESSED LEVEL OF CONSCIOUSNESS#	NOT RELATED/ SAE [H]/ N	Grade 3 (2)/ DOSE NOT CHANGED	N/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (3)/ [redacted]20[redacted] (22)	20[redacted]:10:10 (3)/ 20	免疫系障害/ サイトカイン放出症候群/ CYTOKINES RELEASE SYNDROME#	RELATED/ SAE [O]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

Note: Events are classified using MedDRA 24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Cycle 1-2.
Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Table 72

Serious Adverse Events - GCT3013-04 Expansion Part - Subjects in aNHL Cohorts - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset D/T Resolution D/T (Study Day)	Most Recent Dose D/T (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/A(JAPANESE)/D)	[redacted] (107)/ [redacted] (128)	[redacted]:12:43 (9)/ 22	感染症および寄生虫症/ 肺炎/ PNEUMONIA	RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/A(JAPANESE)/D)	[redacted] (233)/ [redacted] (239)	[redacted]:12:59 (9)/ 7	感染症および寄生虫症/ 気管支炎/ BRONCHITIS	RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/A(JAPANESE)/D)	[redacted] (16)/ [redacted] (19)	[redacted]:10:00 (2)/ 4	感染症および寄生虫症/ 尿路感染/ URINARY TRACT INFECTION#	RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted]	[redacted] (29)/ [redacted] (45)	[redacted]:10:00 (15)/ 17	感染症および寄生虫症/ 尿路感染/ URINARY TRACT INFECTION REACTIVATION#	RELATED/ SAE [H]/ N	Grade 3 (2)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

Note: Events are classified using MedDRA 24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Cycle 1-2.
Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events - GCT3013-04 Expansion Part - Subjects in aNHL Cohorts - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset D/T Resolution D/T (Study Day)	Most Recent Dose D/T (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/A(JAPANESE)/D)	[redacted]20[redacted] (152)	[redacted]20[redacted]:12:46 (54)	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） / 膵癌/ PANCREATIC CANCER#	NOT RELATED/ SAE [H, O]/ N	Grade 3/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (6[redacted]/F/A(JAPANESE)/D)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (17)	[redacted]20[redacted]:10:00 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/A(JAPANESE)/D)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (28)	[redacted]20[redacted]:11:40 (2)/ 13	免疫系障害/ サイトカイン放出症候群/ CRS#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (36)/ [redacted]20[redacted]:15:33 (38)	[redacted]20[redacted]:11:30 (6)/ 3	免疫系障害/ サイトカイン放出症候群/ CRS#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

Note: Events are classified using MedDRA 24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Cycle 1-2.
Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events - GCT3013-04 Expansion Part - Subjects in aNHL Cohorts - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset D/T Resolution D/T (Study Day)	Most Recent Dose D/T (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/A(JAPANESE)/D)	[redacted] (17)/ [redacted] (20)	[redacted] :11:20 (17)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/A(JAPANESE)/D)	[redacted] (37)/ [redacted] (57)	[redacted] :10:35 (9)/ 21	筋骨格系および結合組織障害/ 背部痛/ BACK PAIN#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/A(JAPANESE)/D)	[redacted] (62)/ [redacted] (72)	[redacted] :11:16 (6)/ 11	感染症および寄生虫症/ 帯状疱疹/ SHINGLES	RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/A(JAPANESE)/D)	[redacted] (29)/ [redacted] (30)	[redacted] :13:30 (8)/ 2	臨床検査/ 血小板数減少/ PLATELET COUNT DECREASED#	RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

Note: Events are classified using MedDRA 24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Cycle 1-2.
Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events - GCT3013-04 Expansion Part - Subjects in aNHL Cohorts - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset D/T Resolution D/T (Study Day)	Most Recent Dose D/T (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/A(JAPANESE)/D)	[redacted]20[redacted] (18)/ [redacted]20[redacted] (20)	[redacted]20[redacted]:11:07 (4)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/F/A(JAPANESE)/D)	[redacted]20[redacted] (8)/ [redacted]20[redacted] (11)	[redacted]20[redacted]:13:27 (8)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 3 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/A(JAPANESE)/D)	[redacted]20[redacted] (5)/ [redacted]20[redacted] (7)	[redacted]20[redacted]:12:53 (5)/ 3	神経系障害/ 免疫エフェクター細胞関連神経毒性症候群/ IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (9)/ [redacted]20[redacted] (20)	[redacted]20[redacted]:13:11 (2)/ 12	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 3 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

Note: Events are classified using MedDRA 24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Cycle 1-2.
Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events - GCT3013-04 Expansion Part - Subjects in aNHL Cohorts - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset D/T Resolution D/T (Study Day)	Most Recent Dose D/T (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/A(JAPANESE)/D)		[redacted]:11:00	腎および尿路障害/ 尿管結石症/ URETERAL STONES	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (8[redacted]/M/A(JAPANESE)/D)	[redacted] (203)	[redacted]:11:55 (34)	耳および迷路障害/ 回転性めまい/ VERTIGO	NOT RELATED/ SAE [H]/ N	Grade 3 (2)/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted] (229)/ [redacted]:10:00 (247)	[redacted]:11:57 (19)/ 19	感染症および寄生虫症/ サイトメガロウイルス性腸炎/ CYTOMEGALOVIRUS ENTEROCOLITIS	NOT RELATED/ SAE [O]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (170)	[redacted]:11:55 (1)	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/ 慢性骨髄単球性白血病/ CHRONIC MYELOMONOCYTIC LEUKEMIA	NOT RELATED/ SAE [O]/ N	Grade 2/ DRUG WITHDRAWN	N/ NOT RECOVERED/NOT RESOLVED

Note: Events are classified using MedDRA 24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Cycle 1-2.
Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Table 72

Serious Adverse Events - GCT3013-04 Expansion Part - Subjects in aNHL Cohorts - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset D/T Resolution D/T (Study Day)	Most Recent Dose D/T (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (8[redacted]/M/A(JAPANESE)/D)	[redacted]20[redacted] (223)	[redacted]20[redacted]:12:09 (27)	傷害、中毒および処置合併症/硬膜下血腫/CHRONIC SUBDURAL HEMATOMA(RIGHT)	NOT RELATED/ SAE [O]/ N	Grade 3 (2)/ DOSE NOT CHANGED	Y/ RECOVERING/ RESOLVING
[redacted] (6[redacted]/F/A(JAPANESE)/D)	[redacted]20[redacted] (65)/ [redacted]20[redacted] (76)	[redacted]20[redacted]:16:17 (9)/ 12	感染症および寄生虫症/ 肛門直腸感染/ ANORECTAL INFECTION SUSPECT	RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (127)	[redacted]20[redacted]:14:04 (14)	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/ 扁平上皮癌/ SQUAMOUS CELL CARCINOMA	NOT RELATED/ SAE [O]/ N	Grade 3/ DOSE NOT CHANGED	N/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (16)/ [redacted]20[redacted]:14:30 (19)	[redacted]20[redacted]:13:32 (2)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

Note: Events are classified using MedDRA 24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Cycle 1-2.
Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Table 73

Serious Adverse Events - GCT3013-04 Expansion Part - Subjects in iNHL Cohorts - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset D/T Resolution D/T (Study Day)	Most Recent Dose D/T (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/A(JAPANESE)/F)		[redacted]:12:24	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） / 胃癌/ EARLY GASTRIC CANCER	NOT RELATED/ SAE [O]/ N	Grade 1/ DOSE NOT CHANGED	N/ NOT RECOVERED/NOT RESOLVED
[redacted] (7[redacted]/F/A(JAPANESE)/F)	[redacted] (2)/ [redacted] (4)	[redacted]:12:25 (2)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDOROM#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (16)/ [redacted]:12:00 (17)	[redacted]:10:00 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROM#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/A(JAPANESE)/F)	[redacted] (21)/ [redacted] (22)	[redacted]:11:00 (7)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

Note: Events are classified using MedDRA 24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Cycle 1-2.
Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events - GCT3013-04 Expansion Part - Subjects in iNHL Cohorts - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset D/T Resolution D/T (Study Day)	Most Recent Dose D/T (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/A(JAPANESE)/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (32)	[redacted]20[redacted]:11:10 (2)/ 17	皮膚および皮下組織障害/ 斑状丘疹状皮疹/ RASH MACULOPAPULAR#	RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/A(JAPANESE)/F)	[redacted]20[redacted] (216)/ [redacted]20[redacted]:12:00 (226)	[redacted]20[redacted]:12:02 (11)/ 11	感染症および寄生虫症/ 肺炎球菌性肺炎/ PNEUMOCOCCAL PNEUMONIA	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/A(JAPANESE)/F)	[redacted]20[redacted] (143)/ [redacted]20[redacted] (150)	[redacted]20[redacted]:10:47 (2)/ 8	感染症および寄生虫症/ 帯状疱疹/ HERPES ZOSTER	RELATED/ SAE [H]/ N	Grade 3 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/A(JAPANESE)/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (22)	[redacted]20[redacted]:10:50 (2)/ 7	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [O]/ Y	Grade 3 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

Note: Events are classified using MedDRA 24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Cycle 1-2.
Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events - GCT3013-04 Expansion Part - Subjects in iNHL Cohorts - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset D/T Resolution D/T (Study Day)	Most Recent Dose D/T (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/A(JAPANESE)/F)	[redacted]20[redacted] (2)/ [redacted]20[redacted] (4)	[redacted]20[redacted]:11:45 (2)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ NOT APPLICABLE	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/A(JAPANESE)/F)	[redacted]20[redacted] (20)/ [redacted]20[redacted] (22)	[redacted]20[redacted]:09:55 (6)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/A(JAPANESE)/F)	[redacted]20[redacted] (2)/ [redacted]20[redacted]:11:30 (3)	[redacted]20[redacted]:14:02 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (16)/ [redacted]20[redacted]:10:00 (17)	[redacted]20[redacted]:15:40 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

Note: Events are classified using MedDRA 24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Cycle 1-2.
Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.